It’s less than a year since cannabis was legalised for medical purposes, and investors haven’t let the grass grow beneath their feet. Australia already ranks among the countries with the highest number of recreational users.
It’s less than a year since cannabis was legalised for medical purposes, and investors haven’t let the grass grow beneath their feet. Australia already ranks among the countries with the highest number of recreational users. The history of cannabis cultivation here dates back to the First Fleet, when settlers brought along seeds to make hemp. Now the aptly named weed is at the centre of a growth industry aimed at treating many common ailments.
Let’s get one point straight. The marijuana that is smoked is not the same stuff that could soon ease itching from eczema, let insomniacs sleep or improve cancer treatments. The plants look similar but they have vastly different chemical make-up. Cannabis contains 113 types of a compound called cannabinoid. Just one of those, THC, brings a state of euphoria. Plants can be bred to have thousands of different concentrations and combinations of each compound, giving them the potential to treat many different ills. No one compound works alone. They all do, creating what is called an entourage effect. Now that it’s legal, the challenge is to test exactly which plants have which effects.
Harry Karelis is doing just that. Before the year is out, a company he chairs, Zelda Therapeutics, will start its first clinical trial in partnership with the University of Western Australia on formulations to treat insomnia. The university is a leader in sleep disorders, with its own sleep labs. “Picture a controlled environment where you have a relaxing night’s sleep with 24 leads attached to your brain, your lungs, your heart, your limbs and a camera monitoring your night’s sleep,” says Karelis. “We will be monitoring pretty much everything that is going on, including blood. This will be a randomised, crossover, placebo-controlled trial. That means the gold standard. If we show that our medicine works under those conditions, then it works.”
この記事は Money Magazine Australia の October 2017 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です ? サインイン
この記事は Money Magazine Australia の October 2017 版に掲載されています。
7 日間の Magzter GOLD 無料トライアルを開始して、何千もの厳選されたプレミアム ストーリー、9,000 以上の雑誌や新聞にアクセスしてください。
すでに購読者です? サインイン
An outrageous, beautiful monopoly
Telstra's mobile business is a cash machine with few competitors, giving it the highest returns in the world.
Drop the anchor to judge value
Buying and selling decisions should be based on where a stock price is going, not where it has been.
Powering the AI boom
Beyond the software and chipmakers, where will the energy come from?
Get into life
Tucked inside super are products that can protect you from life's inevitable uncertainties.
Paths to home ownership
Taking the road less travelled can sometimes deliver unexpected benefits.
Sold! Quick ways to add value
Small, strategic changes can have a big impact on the look and feel of your home. And get you a better price on auction day.
Money lessons the kids need to know
Your children can learn a lot from your past money mishaps. Here are eight financial conversations I have had with mine.
Property-investing rules: are they likely to change?
The pressure for the government to curb the tax benefits of tax concessions, such as negative gearing and the capital gains tax discount, is unrelenting. Most recently, independent senators David Pocock and Jacqui Lambie proposed five options for paring back investment property tax concessions, with savings to the Federal budget of up to $60 billion over the next decade.
What's love got to do with it?
A rollercoaster of emotions could be driving poor crypto behaviour.
Are we ready to be cash-free?
Saying goodbye to our piggy banks too soon could leave small businesses in the dark when problems arise.